Loading...
XNYS
AORT
Market cap2.11bUSD
Dec 05, Last price  
44.59USD
1D
-1.81%
1Q
2.53%
Jan 2017
132.85%
Name

Artivion Inc

Chart & Performance

D1W1MN
XNYS:AORT chart
P/E
P/S
5.44
EPS
Div Yield, %
Shrs. gr., 5y
1.94%
Rev. gr., 5y
7.06%
Revenues
389m
+9.75%
69,282,00081,311,00094,763,000105,059,000111,685,000116,645,000119,626,000131,718,000140,763,000144,641,000145,898,000180,380,000189,702,000262,841,000276,222,000253,227,000298,836,000313,789,000354,004,000388,537,000
Net income
-13m
L-56.47%
-19,535,000365,0007,201,00032,908,0008,679,0003,944,0007,371,0007,946,00016,172,0007,322,0004,005,00010,778,0003,704,000-3,805,0001,720,000-16,682,000-14,834,000-19,192,000-30,690,000-13,359,000
CFO
22m
+18.12%
-18,517,000-1,071,0009,292,0009,537,00016,572,00020,837,00016,751,00018,990,00016,772,0008,118,00011,442,00019,719,00010,803,0009,881,00015,827,00012,369,000-2,585,000-5,153,00018,825,00022,236,000
Dividend
Dec 09, 20150.03 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X prosthetic aortic and mitral heart valve, and On-X ascending aortic prosthesis; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita OPEN PLUS and E-vita OPEN NEO, a hybrid stent graft system. The company also provides E-xtra DESIGN ENGINEERING products for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, it offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; and cardiac laser therapy products, such as SolarGen 2100s Console and SoloGrip III disposable handpieces. Further, the company sells CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as offers pyrolytic carbon coating services to other medical device manufacturers. The company serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. Artivion Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.
IPO date
Feb 12, 1993
Employees
1,300
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT